Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AssigneeImmunomedics, Inc.
InventorsDavid M. Goldenberg, Hans J. Hansen
Life of this patent
Estimating the term…
Abstract
The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed.
Claims44
A method for treating a B-cell-related malignancy disease in a human comprising administering to said human either
- (i) a conjugated anti-CD74 antibody or an antigen-binding fragment thereof
- and
- an unconjugated anti-CD20 antibody or an antigen-binding fragment thereof,
- wherein said conjugated anti-CD74 antibody or antigen-binding fragment thereof and said unconjugated anti-CD20 antibody or antigen-binding fragment thereof are administered concurrently or sequentially
- or
- (ii) a conjugated anti-CD20 antibody or an antigen-binding fragment thereof
- and
- an unconjugated anti-CD74 antibody, or an antigen-binding fragment thereof,
- wherein said conjugated anti-CD20 antibody or antigen-binding fragment thereof and said unconjugated anti-CD74 antibody or antigen-binding fragment thereof are administered concurrently or sequentially,
- wherein predosing with a non-radiolabeled antibody is not performed and wherein the unconjugated anti-CD20 or unconjugated anti-CD74 is added as a maintenance therapy to keep proliferating tumor cells from target escape.
A method for treating a B-cell related malignancy disease in a human comprising administering to said human a bispecific antibody that binds to both CD74 and CD20, said bispecific antibody comprising either:
- (i) a conjugated anti-CD74 antibody or antigen-binding fragment thereof and an unconjugated anti-CD20 antibody or antigen binding fragment thereof, or
- (ii) a conjugated anti-CD20 antibody or antigen-binding fragment thereof and an unconjugated anti-CD74 antibody or antigen-binding fragment thereof,
- wherein the unconjugated anti-CD20 or anti-CD74 is a maintenance therapy to keep proliferating tumor cells from target escape.
A method for treating a B-cell related malignancy disease comprising administering to a human a therapeutic composition comprising:
- (a) a pharmaceutically acceptable vehicle containing unconjugated anti-CD20 antibody, or an antigen-binding fragment thereof, or unconjugated single chain antibody fusion protein, said antibody fusion protein comprising a recombinantly produced antigen-binding molecule in which two or more of the same or different single-chain antibodies, or two or more of the same or different antigen-binding fragments are linked,
- wherein said unconjugated antibody or antigen-binding fragment thereof or said unconjugated fusion protein targets CD20, and said fusion protein or antigen-binding fragment comprises the variable domains, or the CDRs of the heavy and light chains of said CD20 antibody;
- and
- (b) a pharmaceutically acceptable vehicle containing a conjugated humanized monoclonal antibody or antigen-binding fragment thereof that binds CD74, said antibody or antigen-binding fragment thereof being conjugated to doxorubicin
- wherein (a) and (b) are administered concurrently or sequentially.
Dependencies are inferred from the claim text.